When considering the subset of patients with ovarian cancer across all dosing groups, increases in afami-cel doses were associated with progressively increasing peak cell persistence and peak IFNγ levels (Supplementary Table 10). The gene discussed is IFNG; the disease is ovarian carcinoma.